Latest Share Chat

REMOVE ADS

Skinbiotherap. Share News (SBTX)

Skinbiotherap. Information

Share Price Information for Skinbiotherap. (SBTX)

Share Price is delayed by 15 minutes

Get Live Data

11.50 0.50 (4.55%)

Bid:

11.00

Ask:

12.00

Spread: 1.00 (9.091%)

Market Cap: £29.80m

Last checked at -

Intraday Skinbiotherap. Share Chart

REMOVE ADS

Skinbiotherap. News

SkinBioTherapeutics begins human study on SkinBiotix

(Sharecast News) - Life science company SkinBioTherapeutics has commenced its human study being carried out on its 'SkinBiotix' technology, it announc...

SkinBioTherapeutics to begin human study this month

(Sharecast News) - Life science company SkinBioTherapeutics updated the market on its stability testing on Monday, reporting that the stability criter...

SkinBioTherapeutics Shares Rise As SkinBiotix Human Study Set To Start

LONDON (Alliance News) - Shares rose in SkinBioTherapeutics PLC on Monday as it said its SkinBiotix technology has met the stability criteria needed f...

SkinBioTherapeutics achieves 'significant' manufacturing scale-up

(Sharecast News) - Skin health-focussed life science company SkinBioTherapeutics updated the market on Thursday, reporting that it had now achieved "s...

SkinBioTherapeutics Achieves "Significant Manufacturing Scale-Up"

LONDON (Alliance News) - SkinBioTherapeutics PLC said Thursday that it achieved "significant" manufacturing scale-up alongside its third party manufac...

SkinBioTherapeutics, Manchester University To Research Skin Aging

LONDON (Alliance News) - SkinBioTherapeutics PLC said Tuesday it will team up with the University of Manchester to to research how aging affects the s...

SkinBioTherapeutics File New Patent Application For SkinBiotix Product

LONDON (Alliance News) - SkinBioTherapeutics PLC said Monday it had filed a new patent application related to its SkinBiotix probiotic bacteria produc...

SkinBioTherapeutics Finalises Plans For SkinBiotix Human Study

LONDON (Alliance News) - SkinBioTherapeutics PLC on Tuesday said it has finished designing a human study planned for its SkinBiotix proposed treatment...